Is it possible to sustain adequate immunosuppressive efficacy minimizing the nephrotoxicity with a regimen including low doses of calcineurin inhibitors or sirolimus?
Jiménez, S.; Zamora, J.; Muriel, A.; Pascual, J.
Nefrologia Publicacion Oficial de la Sociedad Espanola Nefrologia 28(Suppl 2): 40-41
2008
ISSN/ISBN: 0211-6995 PMID: 18457563 Document Number: 622104
Document emailed within 1 workday
Related Documents
Pallardo, L.M.; Sanchez, J.; Garcia, J.; Moreno, R.F.; Rochera, A.; Cabezuelo, J. 1988: Low doses of cyclosporine, azathioprine, and prednisone in renal transplantation: immunosuppressive efficacy and reduced nephrotoxicity Transplantation Proceedings 20(5 Suppl 6: 26-27Ignjatović, L.; Hrvacević, R.; Jovanović, D.; Kovacević, Z.; Vavić, N.; Rabrenović, V.; Tomić, A.; Aleksić, P.; Drasković-Pavlović, B.; Dujić, A.; Karan, Z.; Maksić, D. 2013: Conversion from calcineurin inhibitors to sirolimus of recipients with chronic kidney graft disease grade III for a period 2003-2011 Vojnosanitetski pregled 70(9): 848-853
Zhang, Q.; Xu, B.; Yang, Y.-J.; Qiao, S.-B.; Zhang, R.-Y.; Zhang, J.-S.; Hu, J.; Qin, X.-W.; Chen, J.-L.; Shen, W.-F.; Gao, R.-L. 2008: Long-term efficacy and safety of Chinese made sirolimus eluting stents: results, including off label usage, from two centres over three years Chinese Medical Journal 121(17): 1670-1674
Yun, Y.S.; Kim, B.J.; Hong, S.P.; Lee, T.W.; Lim, C.G.; Kim, M.J. 1996: Changes of bone metabolism indices in patients receiving immunosuppressive therapy including low doses of steroids after renal transplantation Transplantation Proceedings 28(3): 1561-1564
Yang, Y.-J.; Li, L.-X.; He, Q.; Fan, H.; Jin, Z.-K.; Lang, R.; Kou, J.-T.; Li, P.; Xie, D.-H.; Chen, D.-Z. 2007: Sirolimus as primary immunosuppressant for calcineurin inhibitor-related renal insufficiency after liver transplantation Hepatobiliary and Pancreatic Diseases International: Hbpd Int 6(4): 376-378
Carella, A.M.; Podestá, M.; Pollicardo, N.; Pungolino, E.; Raffo, M.R.; Ferrero, R.; Bergamaschi, G.; Rosti, V.; Cazzola, M.; Saglio, G. 1994: Idarubicin-containing regimen and G-CSF are capable of recruiting CD34+/DR- cells with high proliferative potential which sustain Ph-negative polyclonal hematopoiesis Leukemia 8(1): 212-213
Salomon, D.R. 1991: An alternative view minimizing the significance of cyclosporine nephrotoxicity and in favor of enhanced immunosuppression for long-term kidney transplant recipients Transplantation Proceedings 23(4): 2115-2118
Namjud, N.; Chariyavilaskul, P.; Townamchai, N.; Wittayalertpanya, S. 2015: A reduction of asymmetric dimethylarginine in renal transplant recipients receiving sirolimus-based regimen Journal of the Medical Association of Thailand 98(Suppl 1): S9-13
Krämer, B.K.; Jung, B.; Banas, B. 2008: Reduced exposure to calcineurin inhibitors in renal transplantation New England Journal of Medicine 358(23): 2519; Author Reply 2519-2520
Lebwohl, M.; Gower, T. 2006: A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis Medgenmed: Medscape General Medicine 8(4): 8
Fleischer, A.B. 2006: Black box warning for topical calcineurin inhibitors and the death of common sense Dermatology Online Journal 12(6): 2
2003: Calcineurin inhibitors in treatment of atopic dermatitis. Topical corticoids now only in severe outbreaks? MMWFortschrittederMedizin 145(29-30): 62
Nelson, P.A.; Akselband, Y.; Kawamura, A.; Su, M.; Tung, R.D.; Rich, D.H.; Kishore, V.; Rosborough, S.L.; DeCenzo, M.T.; Livingston, D.J. 1993: Immunosuppressive activity of [MeBm2t]1-, D-diaminobutyryl-8-, and D-diaminopropyl-8-cyclosporin analogues correlates with inhibition of calcineurin phosphatase activity Journal of Immunology 150(6): 2139-2147
Tachibana, T. 2004: The effects of calcineurin inhibitors on neurologic and histopathologic outcome after transient spinal cord ischemia in rabbits Hokkaido Journal of Medical Science 79(1): 87-92
Hale, D.A.; Gottschalk, R.; Maki, T.; Monaco, A.P. 1998: Determination of an improved sirolimus (rapamycin)-based regimen for induction of allograft tolerance in mice treated with antilymphocyte serum and donor-specific bone marrow Transplantation 65(4): 473-479
Nachbur, B.; Lebek, G.; Meyer, R.P.; Neiger, M.; Nyffegger, R.; Brentano, M.; Blumer, R. 1973: Clinical study of high doses of gentamicin on oto- and nephrotoxicity in man Schweizerische Rundschau für Medizin Praxis 62(18): 575-577
Barkmann, A.; Nashan, B.; Schmidt, H.H.; Böker, K.H.; Emmanouilidis, N.; Rosenau, J.; Bahr, M.J.; Hoffmann, M.W.; Manns, M.P.; Klempnauer, J.; Schlitt, H.J. 2000: Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil Transplantation 69(9): 1886-1890
Farges, O.; Samuel, D.; Bismuth, H. 1994: Optimal immunosuppressive clinical regimen in liver transplantation Transplantation Proceedings 26(5): 2676-2678
Fasce, E.; Wagemann, H. 1999: Antihypertensive efficacy of monotherapy in increasing doses versus therapy associated in low doses Revista Medica de Chile 127(8): 911-918
Touraine, J.L.; Lefrançois, N.; Dubernard, J.M.; Garnier, J.L.; Eygonnet, J.P.; Gibelin, N.; Bétuel, H.; Traeger, J. 1987: Place of antilymphocyte globulins in the immunosuppressive regimen for kidney transplantation Transplantation Proceedings 19(1 Part 3): 1881